Replies to post #32984 on Marker Therapeutics Inc (MRKR)

[learningcurve2020]

Maybe but it looks like the L trial was a twenty year mess and at best only bought about 3% more five year survivors, and didn't include Optune survivors in that figure. DC is a very expensive and complicated process too as compared to Marker's T cell approach. But I do hear the L story is fantastic for execs.

[microcapbiotech]

Question? What company already completed a P3 with this technology? Thank You